Karyopharm Therapeutics (KPTI)
(Real Time Quote from BATS)
$4.20 USD
+0.17 (4.22%)
Updated Aug 7, 2025 11:40 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KPTI 4.20 +0.17(4.22%)
Will KPTI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPTI
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
Other News for KPTI
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 | KPTI Stock News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KPTI ...
JPMorgan Chase & Co. Expands Stake in Karyopharm Therapeutics Inc.
KPTI Downgraded to Neutral by HC Wainwright & Co. | KPTI Stock News
KPTI Downgraded by Analyst Amid Financial Concerns | KPTI Stock News